(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
12 June 2008 (12.06.2008)

PCT

(10) International Publication Number
WO 2008/068231 A1

(51) International Patent Classification:
C07D 215/22 (2006.01) *A61P 31/06* (2006.01)
A61K 31/47 (2006.01)

(21) International Application Number:
PCT/EP2007/063186

(22) International Filing Date:
3 December 2007 (03.12.2007)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
06125443.9 5 December 2006 (05.12.2006) EP

(71) Applicant *(for all designated States except US)*: **JANSSEN PHARMACEUTICA N.V.** [BE/BE]; Turnhoutseweg 30, B-2340 Beerse (BE).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: **HEGYI, Jean François, Alexandre, Lucas** [BE/BE]; c/o Janssen Pharmaceutica N.V., Turnhoutseweg 30, B-2340 Beerse (BE). **AELTERMAN, Wim, Albert, Alex** [BE/BE]; c/o Janssen Pharmaceutica N.V., Turnhoutseweg 30, B-2340 Beerse (BE). **LANG, Yolande, Lydia** [FR/BE]; c/o Janssen Pharmaceutica N.V., Turnhoutseweg 30, B-2340 Beerse (BE). **STOKBROEKX, Sigrid, Carl, Maria** [BE/BE]; c/o Janssen Pharmaceutica N.V., Turnhoutseweg 30, B-2340 Beerse (BE). **LEYS, Carina** [BE/BE]; c/o Janssen Pharmaceutica N.V., Turnhoutseweg 30, B-2340 Beerse (BE). **VAN REMOORTERE, Peter, Jozef, Maria** [BE/BE]; Jagersdreef 17, B-2950 Kapellen (BE). **FAURE, Anne** [FR/BE]; c/o Janssen Pharmaceutica N.V., Turnhoutseweg 30, B-2340 Beerse (BE).

(74) Common Representative: **JANSSEN PHARMACEUTICA N.V.**; Turnhoutseweg 30, B-2340 Beerse (BE).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:
— *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*
— *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*
— *of inventorship (Rule 4.17(iv))*

Published:
— *with international search report*

(54) **Title:** FUMARATE SALT OF (ALPHA S, BETA R)-6-BROMO-ALPHA-[2-(DIMETHYLAMINO)ETHYL]-2-METHOXY-ALPHA-1-NAPHTHALENYL-BETA-PHENYL-3-QUINOLINEETHANOL

(57) **Abstract:** The present invention relates to the fumarate salt of (alpha S, beta R)-6-bromo-alpha- [2-(dimethylamino)ethyl] -2-methoxy-alpha- 1 -naphthalenyl-beta-phenyl-3 - quinolineethanol, pharmaceutical compositions comprising as active ingredient said salt and to processes for their preparation.

WO 2008/068231 A1